Chronic HCV infection is a global health problem that affects> 184 million people worldwide.
HCV is associated with several hepatic and extrahepatic disorders, including several …

Chronic infection with hepatitis C virus is a major cause of liver disease and hepatocellular
carcinoma worldwide. After the discovery of hepatitis C virus 3 decades ago, the …

The availability of direct-acting antiviral agents for the treatment of hepatitis C virus (HCV)
infection has resulted in a profound shift in the approach to the management of this infection …

PURPOSE Two anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapies are approved
for diffuse large B-cell lymphoma, axicabtagene ciloleucel (axi-cel) and tisagenlecleucel; …

Introduction The COVID-19 pandemic has disrupted healthcare services, reducing
opportunities to conduct routine hepatitis C virus antibody screening, clinical care, and …

Abstract Purpose of Review This article reviews recent epidemiologic trends in HIV and
hepatitis C virus (HCV) and strategies for treatment and prevention of these infections as …

The advent of direct-acting antiviral therapy for hepatitis C virus (HCV) has generated
tremendous interest in transplanting organs from HCV-infected donors. We conducted a …

Background Eradication of hepatitis C virus (HCV) infection via interferon‐based treatment
lowers hepatocellular carcinoma risk; some research suggests this effect extends to …

Barriers remain in the hepatitis C virus (HCV) cascade of care (CoC), limiting the overall
impact of direct acting antivirals. This study examines movement between the stages of the …

Background Despite the availability of new direct-acting antiviral (DAA) regimens, changes
in DAA reimbursement criteria, and a public health focus on hepatitis C virus (HCV) …